McKesson settles state lawsuit for allegedly turning a blind eye to suspicious opioid sales

Opioid crisis
McKesson, without admitting liability or wrongdoing, has settled litigation with West Virginia that accused it lax supply chain oversight when it came to its lucrative sales of opioids in the state. (Maria Fabrizio for KHN)

Drug distributor McKesson, which has had some serious opioid habits, has extricated itself from another piece of litigation tied to the nation’s addiction epidemic.   

The company on Friday agreed to pay $37 million over five years to settle a lawsuit with West Virginia which accused the distributor of falling short on investigating and reporting suspicious drug orders as required by law and so playing a major role in the state’s struggles with the highly addictive drugs.

It will pay $14.5 million up front and another $4.5 million a year for the next five years. The money will go toward the state’s “fight against drug abuse in West Virginia,” including rehab services and job training. The state, which has the highest rate of opioid overdoses in the country, accused the wholesaler of distributing enough hydrocodone and oxycodone to treat every legitimate patient in the state with nearly 3,000 doses, the New York Times reports.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

McKesson, however, was allowed to settle the accusation without admitting any wrongdoing.

“The agreement does not include any admission of liability, and McKesson expressly denies wrongdoing,” the company said in a statement.

It pointed to its enhancements to protect the “integrity of the supply chain and preventing diversion,” and said it is working to end this national crisis.

RELATED: McKesson paying record $150M to settle with feds over opioid sales

Some of those enhancements came after pressure from the Justice Department. In 2017, the company agreed to pay $150 million in penalties, and to suspend sales of opioids in Colorado, Ohio, Michigan and Florida because of its violations of the Controlled Substances Act (CSA). The feds said at the time that McKesson agreed to certain improvements to its system, but more importantly, was required to hire “an independent monitor to assess compliance—the first independent monitor of its kind in a CSA civil penalty settlement.”

Then last year, one of the company’s facilities was issued a warning letter for failing to sufficiently investigate reports of tampering of bottles distributed by the plant that were supposed to contain opioids but instead contained over-the-counter naproxen. That failure led to a verbal lashing by the FDA Commissioner Scott Gottlieb who called McKesson’s lack of controls a violation of law and “simply unacceptable.”

All of the major distributors, as well as many of the makers of the pain killers, have settled or are facing similar accusations.

Read more on

Suggested Articles

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its…

Mallinckrodt’s Acthar Gel has seen its share of lawsuits, but the company was happy to launch another—this time to defend its Medicaid business.